Erythropoietin biosimilar - Pooyesh Darou
Latest Information Update: 20 Sep 2016
At a glance
- Originator Pooyesh Darou
- Class Antianaemics; Erythropoietins
- Mechanism of Action Erythropoietin receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 23 Jul 2015 Pooyesh Darou completes enrolment in its phase I/II trial for Solid tumours in Iran (IRCT2015061822805N1)
- 21 Apr 2014 Phase-I/II clinical trials in Solid tumours in Iran (SC) (IRCT2015061822805N1)